DeepMed Research

BRISTOL MYERS SQUIBB

🇺🇸United States

Country: 🇺🇸United States

Ownership: -

Established: 1989-01-01

Employees: 30K

Market Cap: $97.5B

Website: https://www.bms.com/

Clinical Trials

The Safety and Effectiveness of Lamivudine Plus Stavudine or Zidovudine in HIV-Infected Patients Who Have Taken Zidovudine

Phase 3

Completed

Conditions: HIV Infections

First Posted Date: 2001-08-31

Last Posted Date: 2011-05-04

Lead Sponsor: Bristol-Myers Squibb

Target Recruit Count: 80

Registration Number: NCT00002371

Locations: 🇺🇸
Harbor UCLA Med Ctr, Torrance, California, United States
🇺🇸
SUNY at Stony Brook / Division of Infectious Diseases, Stony Brook, New York, United States
🇨🇦
Montreal Gen Hosp / Div of Clin Immuno and Allergy, Montreal, Quebec, Canada

and more 5 locations

A Pilot Study to Compare the Antiviral and Immunologic Effects of Stavudine ( d4T ) Versus Placebo in Subjects With Evidence of Recent HIV Infection.

Not Applicable

Completed

Conditions: HIV Infections

First Posted Date: 2001-08-31

Last Posted Date: 2011-04-14

Lead Sponsor: Bristol-Myers Squibb

Target Recruit Count: 40

Registration Number: NCT00002349

Locations: 🇺🇸
Naval Med Ctr, Portsmouth, Virginia, United States
🇺🇸
Northwest Med Ctr, Seattle, Washington, United States
🇺🇸
San Diego Naval Hosp, San Diego, California, United States

The Safety and Effectiveness of Didanosine Plus Stavudine Plus Delavirdine Mesylate Plus MKC-442 in HIV-Infected Patients Who Have Not Had Success With Protease Inhibitors

Phase 2

Terminated

Conditions: HIV Infections

First Posted Date: 2001-08-31

Last Posted Date: 2008-08-14

Lead Sponsor: Bristol-Myers Squibb

Target Recruit Count: 25

Registration Number: NCT00002420

Locations: 🇺🇸
Pacific Oaks Med Group, Beverly Hills, California, United States

The Safety and Effectiveness of Didanosine Plus Stavudine Plus Nevirapine Combined With MKC-442 in HIV-Infected Patients Who Have Not Had Success With Protease Inhibitors

Phase 2

Terminated

Conditions: HIV Infections

First Posted Date: 2001-08-31

Last Posted Date: 2008-08-14

Lead Sponsor: Bristol-Myers Squibb

Target Recruit Count: 25

Registration Number: NCT00002418

Locations: 🇺🇸
Univ of Colorado / Health Science Ctr, Denver, Colorado, United States
🇺🇸
Brown Univ School of Medicine, Providence, Rhode Island, United States
🇺🇸
AIDS Research Consortium of Atlanta, Atlanta, Georgia, United States

and more 2 locations

A Study Comparing Megestrol Acetate at 800 mg/Day, and Placebo in AIDS Patients With Anorexia and Cachexia

Phase 3

Completed

Conditions: Cachexia
HIV Infections
Anorexia

First Posted Date: 2001-08-31

Last Posted Date: 2007-10-02

Lead Sponsor: Bristol-Myers Squibb

Registration Number: NCT00002067

Locations: 🇺🇸
Dr Mark Goldstein, Los Angeles, California, United States
🇺🇸
Eisenhower Med Ctr, Rancho Mirage, California, United States
🇺🇸
Northwestern Univ Med School, Chicago, Illinois, United States

and more 11 locations

A Study of ddI in Patients With AIDS Who Become Sicker While Taking Zidovudine

Not Applicable

Completed

Conditions: HIV Infections
Leukoencephalopathy, Progressive Multifocal

First Posted Date: 2001-08-31

Last Posted Date: 2007-10-02

Lead Sponsor: Bristol-Myers Squibb

Registration Number: NCT00002274

Locations: 🇺🇸
Bristol - Myers Squibb Co, Princeton, New Jersey, United States

Nystatin Pastilles for the Prevention of Oral Candidiasis in Patients With AIDS or ARC

Not Applicable

Completed

Conditions: Candidiasis, Oral
HIV Infections

First Posted Date: 2001-08-31

Last Posted Date: 2007-10-02

Lead Sponsor: Bristol-Myers Squibb

Registration Number: NCT00002057

Locations: 🇺🇸
Birmingham Veterans Administration Med Ctr / Univ of Alabama, Birmingham, Alabama, United States
🇺🇸
Bristol - Myers Squibb Co, Princeton, New Jersey, United States

A Study of BV-araU in the Treatment of Varicella-Zoster Viral Disease (VZV) in HIV-Infected Children Who Have Not Had Success With or Who Cannot Take Other Treatments for VZV

Phase 3

Completed

Conditions: HIV Infections
Chickenpox

First Posted Date: 2001-08-31

Last Posted Date: 2007-10-02

Lead Sponsor: Bristol-Myers Squibb

Registration Number: NCT00002358

Locations: 🇺🇸
Bristol - Myers Squibb Co, Wallingford, Connecticut, United States

A Comparison of Epivir Plus Crixivan Combined With Zerit or Retrovir in HIV-Infected Patients Who Have Never Taken Anti-HIV Drugs

Not Applicable

Completed

Conditions: HIV Infections

First Posted Date: 2001-08-31

Last Posted Date: 2007-10-02

Lead Sponsor: Bristol-Myers Squibb

Target Recruit Count: 200

Registration Number: NCT00002369

Locations: 🇵🇷
San Juan AIDS Program, Santurce, Puerto Rico
🇺🇸
Boston Univ Med Ctr Hosp / Evans - 556, Boston, Massachusetts, United States
🇺🇸
HIV Clinical Research Ctr, Fort Lauderdale, Florida, United States

and more 8 locations

A Comparison of Two Anti-HIV Triple-Drug Combinations in HIV-Infected Patients

Not Applicable

Completed

Conditions: HIV Infections

First Posted Date: 2001-08-31

Last Posted Date: 2007-10-02

Lead Sponsor: Bristol-Myers Squibb

Target Recruit Count: 200

Registration Number: NCT00002168

Locations: 🇺🇸
Univ of Nebraska, Omaha, Nebraska, United States
🇺🇸
Anderson Clinical Research, Washington, District of Columbia, United States
🇵🇷
Hosp Regional de Ponce - Area Vieja, Ponce, Puerto Rico

and more 10 locations

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy